HK Stock Market Move | Lae Pharmaceuticals (02105) surged more than 5% in the morning. The clinical research results of LAE002 have been published in the journal "Nature Communications."

Kai Medical (02105) rose more than 5% in the morning, as of the time of writing, it increased by 4.82% to HK$12.82, with a turnover of HK$12.53 million. On the news front, the international scientific journal "Nature Communications" published online on February 6th a study led by academician Xu Binghe from the Chinese Academy of Engineering and the Cancer Hospital of the Chinese Academy of Medical Sciences. The study titled "Afuresertib combined with fulvestrant in the treatment of HR+HER2- advanced breast cancer: a phase Ib trial" showed that the combination therapy demonstrated encouraging anti-tumor activity and good safety characteristics in patients with advanced breast cancer. Public information shows that LAE002 (Afuresertib) is a potent AKT inhibitor developed by Kai Medical. The III clinical trial AFFIRM-205 led by academician Xu Binghe, which combines LAE002 with fulvestrant, targeting patients with PIK3CA/AKT1/PTEN pathway alterations in HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC), is progressing smoothly. Enrollment for the III phase was completed in December 2025, with the aim of releasing top-line data in the first half of this year and submitting a New Drug Application to the China National Medical Products Administration Drug Evaluation Center in mid-year. In November 2025, Kai Medical signed an exclusive licensing agreement with Qilu Pharmaceutical in China to accelerate the commercialization of LAE002.